Back to resultsA Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures (Infuse)
Primary Purpose
Non Union Diaphyseal Fractures
Status
Withdrawn
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Infuse Bone Morphogenic Protein (BMP) 2
iliac crest autograft
Sponsored by
About this trial
This is an interventional treatment trial for Non Union Diaphyseal Fractures focused on measuring Infuse, cost analysis, Non union diaphyseal fracture, The efficacy of Infuse BMP 2 in Non union diaphyseal fractures. Also the cost analysis with the amount of time spent in hospital post op.
Eligibility Criteria
Inclusion Criteria:
Patients must meet all of the following criteria to be eligible for entry into the study:
a) Patients must require open surgical treatment of non-union of a diaphyseal fracture of the tibia, humerus, femur, radius or ulna sustained secondary to trauma.
c) Patients must be candidates for surgical treatment with an intramedullary nail or locked or unlocked plate.
d) Patients must have a fracture of the diaphysis as defined for that specific bone.
e) Patients must show radiographic evidence of skeletal maturity (closed epiphyseal plates).
Exclusion Criteria:
Patients with any of the following criteria, are not eligible for entry into the study:
- Patients requiring mechanical fixation other than Intramedullary nailing or plating (i.e. no external fixation)
- Patients with fractures that fall outside the diaphysis defined for the specific bone in question, i.e. no metaphyseal fractures.
- Patients with segmental circumferential bone loss >4cm.
- Patients whose fractures are the result of a tumour
- Infection per se, does not result in exclusion but it must be treated and the soft tissue envelope closed prior to randomization
- Patients with known metabolic bone disease (other than osteoporosis) which would negatively impact on the bone healing process.
- Patients with known sensitivity to collagen.
- Patients who are pregnant or breastfeeding at the time of study enrolment.
- Patients currently being treated with radiation, chemotherapy, immunosuppression, or steroid therapy.
- Patients receiving any other investigational drug or treatment.
- Patients who have other injuries or conditions such as they are unable to communicate or consent
m)Patients with known breast or prostate cancer
f) Patients must be able and willing to provide informed consent, to complete study assessments, and to be followed for the period of the study.
Sites / Locations
- Halifax Infirmary
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1 Infuse
2 Iliac crest autograft
Arm Description
The patient will receive BMP 2 with allograft
Autograft from Patients Iliac Crest and allograft
Outcomes
Primary Outcome Measures
cost analysis based on length of hospital stay, allograft, blood products and costs associated with complications and/ or re-admission.
Secondary Outcome Measures
Secondary efficacy end points will be the radiographic assessment of healing (RUST scale), the clinical assessment of weight-¬bearing status at 6 months post treatment, and the incidence of additional surgical/medical interventions to promote healing.
Full Information
NCT ID
NCT00856479
First Posted
February 26, 2009
Last Updated
November 8, 2022
Sponsor
Ross Leighton
Collaborators
Canadian Orthopaedic Trauma Society
1. Study Identification
Unique Protocol Identification Number
NCT00856479
Brief Title
A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures
Acronym
Infuse
Official Title
A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Study never started
Study Start Date
March 2009 (undefined)
Primary Completion Date
March 2010 (Anticipated)
Study Completion Date
March 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ross Leighton
Collaborators
Canadian Orthopaedic Trauma Society
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
We are inviting individuals such as yourself, who have diaphyseal fracture (broken bone) with a non union to participate in this research study. A non-union is a lack of bone healing (bone growth where the break in the bone occurred) after 3 months after the operation. The diaphyseal is an area of a specific bone (usually near the middle) where the fracture occurred. The bones we are interested in are the clavicle (collar bone), tibia (lower leg), femur (upper leg), humerus (upper arm) and forearm (lower arm). Treatment goals for these types of fractures are to minimize later surgeries, to assist the healing process, and to decrease the time to healing. The ability of a patient with non-union (lack of bone healing after 3 months post operation) to return to the work force and to normal activities more quickly not only has a good financial impact on society (community), but also improves over-all physical and mental well-being of the patients.
"Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.
Although the safety and efficacy of Infuse has been demonstrated through numerous pre-clinical studies, further human clinical trial is needed to evaluate the safety and the power to produce effects of this product particularly with respect to non unions of long bones. The purpose of this study is to evaluate the safety and the power to produce effects of Infuse implanted during treatment of long bone non unions to reduce later surgeries required to augment the healing process and to accelerate the time to healing.
Given this, the orthopaedic community has planned this study in order to scientifically establish the most effective treatment method to restore function after this type of injury.
Detailed Description
We propose a multi-centre Canadian randomized Study wherein 80 patients are randomized (put in groups by no standard pattern ie. flipping a coin) to receive both autograft (sample of your own bone: iliac crest) and allograft (bone chips from bone bank) or "infuse" (synthetic bone morphogenic protein) and allograft using locked plates. Locked plates are surgical plates placed on the fracture in which the screws lock into the plate when they have been completely screwed into the bone through holes on the plate. Our objective is to assess the total cost of the patients treated in both study group and the benefits of the Infuse by comparing the new bone formation in the fracture site.
We will monitor critical aspects of operative care and rehabilitation at regular intervals, up to 2 year after surgery. We will independently monitor revision surgery (surgeries to repair a previous surgery) rates. We will also assess patients for functional health and quality of life outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Union Diaphyseal Fractures
Keywords
Infuse, cost analysis, Non union diaphyseal fracture, The efficacy of Infuse BMP 2 in Non union diaphyseal fractures. Also the cost analysis with the amount of time spent in hospital post op.
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1 Infuse
Arm Type
Active Comparator
Arm Description
The patient will receive BMP 2 with allograft
Arm Title
2 Iliac crest autograft
Arm Type
Active Comparator
Arm Description
Autograft from Patients Iliac Crest and allograft
Intervention Type
Device
Intervention Name(s)
Infuse Bone Morphogenic Protein (BMP) 2
Intervention Description
"Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.
Intervention Type
Procedure
Intervention Name(s)
iliac crest autograft
Intervention Description
A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
Primary Outcome Measure Information:
Title
cost analysis based on length of hospital stay, allograft, blood products and costs associated with complications and/ or re-admission.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Secondary efficacy end points will be the radiographic assessment of healing (RUST scale), the clinical assessment of weight-¬bearing status at 6 months post treatment, and the incidence of additional surgical/medical interventions to promote healing.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must meet all of the following criteria to be eligible for entry into the study:
a) Patients must require open surgical treatment of non-union of a diaphyseal fracture of the tibia, humerus, femur, radius or ulna sustained secondary to trauma.
c) Patients must be candidates for surgical treatment with an intramedullary nail or locked or unlocked plate.
d) Patients must have a fracture of the diaphysis as defined for that specific bone.
e) Patients must show radiographic evidence of skeletal maturity (closed epiphyseal plates).
Exclusion Criteria:
Patients with any of the following criteria, are not eligible for entry into the study:
Patients requiring mechanical fixation other than Intramedullary nailing or plating (i.e. no external fixation)
Patients with fractures that fall outside the diaphysis defined for the specific bone in question, i.e. no metaphyseal fractures.
Patients with segmental circumferential bone loss >4cm.
Patients whose fractures are the result of a tumour
Infection per se, does not result in exclusion but it must be treated and the soft tissue envelope closed prior to randomization
Patients with known metabolic bone disease (other than osteoporosis) which would negatively impact on the bone healing process.
Patients with known sensitivity to collagen.
Patients who are pregnant or breastfeeding at the time of study enrolment.
Patients currently being treated with radiation, chemotherapy, immunosuppression, or steroid therapy.
Patients receiving any other investigational drug or treatment.
Patients who have other injuries or conditions such as they are unable to communicate or consent
m)Patients with known breast or prostate cancer
f) Patients must be able and willing to provide informed consent, to complete study assessments, and to be followed for the period of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ross K Leighton, MD
Organizational Affiliation
CDHA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Halifax Infirmary
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3h 1V7
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures
We'll reach out to this number within 24 hrs